Lonza Group AG · ISIN: CH0013841017 · EQS - Company News

Lonza Nominates David Meline as Independent Board Member

Lonza Group AG / Key word(s): Personnel Lonza Nominates David Meline as Independent Board Member 03.10.2024 / 09:00 CET/CEST David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors Olivier Verscheure will not stand for re-election at the 2025 Annual General Meeting Basel, Switzerland, 3 October 2024 - Today, Lonza’s Board of Directors announced the nomination of David Meline as an Independent Member of the Board. The Boar...

SIX:LONN Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Lonza Group AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
03 October 2024 09:00AM
Lonza Nominates David Meline as Independent Board Member
CH0013841017
Lonza Group AG / Key word(s): Personnel Lonza Nominates David Meline as Independent Board Member 03.10.2024 / 09:00 CET/CEST David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors Olivier Verscheure will not stand for re-election at the 2025 Annual General Meeting Basel, Sw...
Lonza Group AG
About the publication
01 October 2024 04:45PM
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
CH0013841017
Lonza Group AG / Key word(s): Acquisition Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche 01.10.2024 / 16:45 CET/CEST The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on...
Lonza Group AG
About the publication
24 September 2024 02:00PM
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
CH0013841017
Lonza Group AG / Key word(s): Partnership Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) 24.09.2024 / 14:00 CET/CEST Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply CASGEVY® will be manufactured at Lonza...
Lonza Group AG
About the publication
28 August 2024 06:31PM
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds
CH0013841017
Lonza Group AG / Key word(s): Bond Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds 28.08.2024 / 18:31 CET/CEST Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche EUR 1.2 billion straight bonds....
Lonza Group AG
About the publication
25 July 2024 06:55AM
Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Lonza delivered sales of CHF 3.1 billion, growing 1.8%1 CER CHF 893 million CORE EBITDA resulted in a margin of 29.2% Robust performance in CDMO business, with headwinds in the capsules business within the Capsules & Health Ingredients (CHI) division Solid free cash flow at CHF 296 million Group O...
Lonza Group AG
About the publication
08 May 2024 03:00PM
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
CH0013841017
Lonza Group AG / Key word(s): AGMEGM Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved 08.05.2024 / 15:00 CET/CEST Jean-Marc Huët was elected as Chairman of the Board of Directors  Shareholders re-elected all members of the Board of Directors standing for re-elect...
Lonza Group AG
About the publication
17 April 2024 07:00PM
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
CH0013841017
Lonza Group AG / Key word(s): Bond/Financing Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon 17.04.2024 / 19:00 CET/CEST Basel, Switzerland, 17 April 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 1 billion straight bond. The...
Lonza Group AG
About the publication
03 April 2024 07:00AM
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Annual General Meeting will take place on 8 May 2024 at the Congress Center in Basel, Switzerland Albert M. Baehny will not stand for re-election as Chairman of the Board of Directors. Jean-Marc Huët proposed as new Chairman of Lonza All current Board Members except for Albert M. Baehny proposed for re-e...
Lonza Group AG
About the publication
02 April 2024 07:00AM
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Wolfgang Wienand, currently CEO of Swiss CDMO Siegfried Holding AG, will become Chief Executive Officer of Lonza in the summer of 2024 Albert M. Baehny will retire from Lonza following a transition period Basel, Switzerland, 2 April 2024 – The Board of Directors of Lonza today announced that Wolfgang Wien...
Lonza Group AG
About the publication
20 March 2024 07:00AM
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion in cash Vacaville (US) site is one of the largest biologics manufacturing facilities in the world by volume Acquisition is set to increase Lonza’s large-scale biologics manufactu...
Lonza Group AG
About the publication
26 January 2024 07:01AM
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Longstanding Chairman of Lonza, Albert Baehny will not stand for re-election Jean-Marc Huët, currently Chairman of Heineken N.V. with strong international leadership track record to be proposed as the new Chairman of Lonza at the 2024 AGM Albert Baehny to remain ad interim CEO of Lonza until the new CEO ...
Lonza Group AG
About the publication
26 January 2024 06:50AM
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8%  Continued growth investment with 2023 CAPEX at 25% of sales Solid free cash flow at CHF 329 million Proposed 14% dividend increase from CHF 3.50 to CHF 4.00 per share Retur...
Lonza Group AG
About the publication
06 November 2023 06:30PM
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
CH0013841017
Lonza Group AG / Key word(s): Bond/Financing Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds 06.11.2023 / 18:30 CET/CEST Basel, Switzerland, 06 November 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million dual-tranche strai...
Lonza Group AG
About the publication
17 October 2023 07:00AM
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 32–34% CORE EBITDA margin and double-digit ROIC Outlook 2023: higher end of mid-to-high single-digit CER sales growth and 28 to 29% CORE EBITDA margin Business growth in 2024 will be offset ...
Lonza Group AG
About the publication
13 October 2023 08:00AM
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
CH0013841017
Lonza Group AG / Key word(s): Expansion Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer 13.10.2023 / 08:00 CET/CEST The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion...
Lonza Group AG
About the publication
21 September 2023 07:00AM
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an overview of Lonza’s offerings, capabilities, markets and sources of competitive advantage Lonza reconfirms Outlook 2023 at mid-to-high single-digit CER sales growth and 28 to 29% CORE EBITDA...
Lonza Group AG
About the publication
18 September 2023 07:00AM
Board Announcement
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR CEO Pierre-Alain Ruffieux to leave Lonza Albert M. Baehny to step in as CEO ad interim Capital Markets Day on October 17 confirmed Basel, Switzerland, 18 September 2023 – Lonza announced today that Pierre-Alain Ruffieux, CEO, will leave the company at the end of September by mutual agreement. The Board of ...
Lonza Group AG
About the publication
21 July 2023 07:00AM
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying sales growth2 CHF 922 million CORE EBITDA resulted in a margin of 30% Good momentum in commercial CDMO business Group Outlook 2023 update: mid-to-high single-digit CER sales growth an...
Lonza Group AG
About the publication
21 July 2023 07:00AM
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying sales growth2 CHF 922 million CORE EBITDA resulted in a margin of 30% Good momentum in commercial CDMO business Group Outlook 2023 update: mid-to-high single-digit CER sales growth an...
Lonza Group AG
About the publication
01 June 2023 07:00AM
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
CH0013841017
Lonza Group AG / Key word(s): Acquisition/Mergers & Acquisitions Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering 01.06.2023 / 07:00 CET/CEST Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs)   Acquisition will further strengthen Lonza’s biocon...
Lonza Group AG
About the publication
01 June 2023 07:00AM
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
CH0013841017
Lonza Group AG / Key word(s): Acquisition/Mergers & Acquisitions Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering 01.06.2023 / 07:00 CET/CEST Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs)   Acquisition will further strengthen Lonza’s biocon...
Lonza Group AG
About the publication
10 May 2023 07:00AM
Business Performance In Line With  Full-Year Trajectory
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Robust commercial demand, with softer early-stage demand due to biotech funding constraints Growth project portfolio progressing in line with plan Outlook 2023 reiterated, with high single-digit CER sales growth and CORE EBITDA margin of 30 to 31% Basel, Switzerland, 10 May 2023 – In its quarterly qualitat...
Lonza Group AG
About the publication
10 May 2023 07:00AM
Business Performance In Line With  Full-Year Trajectory
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Robust commercial demand, with softer early-stage demand due to biotech funding constraints Growth project portfolio progressing in line with plan Outlook 2023 reiterated, with high single-digit CER sales growth and CORE EBITDA margin of 30 to 31% Basel, Switzerland, 10 May 2023 – In its quarterly qualitat...
Lonza Group AG
About the publication
05 May 2023 03:00PM
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
CH0013841017
Lonza Group AG / Key word(s): AGMEGM Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted 05.05.2023 / 15:00 CET/CEST Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors A divide...
Lonza Group AG
About the publication
05 May 2023 03:00PM
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
CH0013841017
Lonza Group AG / Key word(s): AGMEGM Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted 05.05.2023 / 15:00 CET/CEST Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors A divide...
Lonza Group AG
About the publication
20 April 2023 06:30PM
Lonza Increases Straight Bond by CHF 150 Million
CH0013841017
Lonza Group AG / Key word(s): Bond/Financing Lonza Increases Straight Bond by CHF 150 Million 20.04.2023 / 18:30 CET/CEST Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 m...
Lonza Group AG
About the publication
20 April 2023 06:30PM
Lonza Increases Straight Bond by CHF 150 Million
CH0013841017
Lonza Group AG / Key word(s): Bond/Financing Lonza Increases Straight Bond by CHF 150 Million 20.04.2023 / 18:30 CET/CEST Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 m...
Lonza Group AG
About the publication
31 March 2023 07:00AM
Lonza Launches Share Buyback Program of up to CHF 2 Billion
CH0013841017
Lonza Group AG / Key word(s): Corporate Action Lonza Launches Share Buyback Program of up to CHF 2 Billion 31.03.2023 / 07:00 CET/CEST Basel, Switzerland, 31 March 2023 – On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong balance sheet and ...
Lonza Group AG
About the publication
31 March 2023 07:00AM
Lonza Launches Share Buyback Program of up to CHF 2 Billion
CH0013841017
Lonza Group AG / Key word(s): Corporate Action Lonza Launches Share Buyback Program of up to CHF 2 Billion 31.03.2023 / 07:00 CET/CEST Basel, Switzerland, 31 March 2023 – On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong balance sheet and ...
Lonza Group AG
About the publication
29 March 2023 09:00AM
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
CH0013841017
Lonza Group AG / Key word(s): Expansion Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH) 29.03.2023 / 09:00 CET/CEST Lonza increases capacity and capabilities in Visp (CH) with the completion of a new line for cGMP clinical and commercial drug product manufacturing   The line is fully operati...
Lonza Group AG
About the publication
29 March 2023 09:00AM
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
CH0013841017
Lonza Group AG / Key word(s): Expansion Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH) 29.03.2023 / 09:00 CET/CEST Lonza increases capacity and capabilities in Visp (CH) with the completion of a new line for cGMP clinical and commercial drug product manufacturing   The line is fully operati...
Lonza Group AG
About the publication
27 March 2023 07:00AM
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of Directors, all current Board Members proposed for re-election KPMG proposed for re-election as auditors for the financial year 2023, with Del...
Lonza Group AG
About the publication
27 March 2023 07:00AM
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of Directors, all current Board Members proposed for re-election KPMG proposed for re-election as auditors for the financial year 2023, with Del...
Lonza Group AG
About the publication
16 February 2023 02:00PM
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
CH0013841017
Lonza Group AG / Key word(s): Expansion Lonza Completes Expansion of Conjugation Facility in Visp (CH) 16.02.2023 / 14:00 CET/CEST Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates The Visp (CH) investment includes two manufacturin...
Lonza Group AG
About the publication
16 February 2023 02:00PM
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
CH0013841017
Lonza Group AG / Key word(s): Expansion Lonza Completes Expansion of Conjugation Facility in Visp (CH) 16.02.2023 / 14:00 CET/CEST Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates The Visp (CH) investment includes two manufacturin...
Lonza Group AG
About the publication
08 February 2023 06:30PM
​​Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon​
CH0013841017
Lonza Group AG / Key word(s): Bond/Financing ​​Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon​ 08.02.2023 / 18:30 CET/CEST Basel, Switzerland, 08 February 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million straight-bond issu...
Lonza Group AG
About the publication
08 February 2023 06:30PM
​​Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon​
CH0013841017
Lonza Group AG / Key word(s): Bond/Financing ​​Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon​ 08.02.2023 / 18:30 CET/CEST Basel, Switzerland, 08 February 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million straight-bond issu...
Lonza Group AG
About the publication
25 January 2023 07:00AM
Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR In 2022, Lonza delivered CHF 6.2 billion sales and 15.1%1 CER sales growth CHF 2.0 billion CORE EBITDA resulted in a margin of 32.1%  Growth investment continues as 2022 CAPEX reached 30% of sales Group Outlook 2023: high single-digit CER sales growth and CORE EBITDA margin of 30 to 31% Mid-Term Guidan...
Lonza Group AG
About the publication
01 November 2022 07:00AM
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
CH0013841017
Lonza Group AG / Key word(s): Product Launch Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine 01.11.2022 / 07:00 CET/CEST Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sensitive APIs Innovative Capsugel® ...
Lonza Group AG
About the publication
01 November 2022 07:00AM
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
CH0013841017
Lonza Group AG / Key word(s): Product Launch Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine 01.11.2022 / 07:00 CET/CEST Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sensitive APIs Innovative Capsugel® ...
Lonza Group AG
About the publication
12 September 2022 07:00AM
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
CH0013841017
Lonza Group AG / Key word(s): Personnel Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division 12.09.2022 / 07:00 CET/CEST Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringi...
Lonza Group AG
About the publication
12 September 2022 07:00AM
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
CH0013841017
Lonza Group AG / Key word(s): Personnel Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division 12.09.2022 / 07:00 CET/CEST Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringi...
Lonza Group AG
About the publication
06 September 2022 07:00AM
Lonza and Touchlight collaborate on end-to-end mRNA offering
CH0013841017
Lonza Group AG / Key word(s): Partnership Lonza and Touchlight collaborate on end-to-end mRNA offering 06.09.2022 / 07:00 CET/CEST Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic...
Lonza Group AG
About the publication
06 September 2022 07:00AM
Lonza and Touchlight collaborate on end-to-end mRNA offering
CH0013841017
Lonza Group AG / Key word(s): Partnership Lonza and Touchlight collaborate on end-to-end mRNA offering 06.09.2022 / 07:00 CET/CEST Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic...
Lonza Group AG
About the publication
22 July 2022 07:01AM
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1%  H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments Group Outlook 2022 confirmed at low to mid-teens CER sales growth and CORE EBITDA m...
Lonza Group AG
About the publication
22 July 2022 07:01AM
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
CH0013841017
Ad hoc announcement pursuant to Art. 53 LR In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1%  H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments Group Outlook 2022 confirmed at low to mid-teens CER sales growth and CORE EBITDA m...
Lonza Group AG
About the publication
01 July 2022 08:00AM
Maria Soler Nunez appointed as Head, Group Operations
CH0013841017
Lonza Group AG / Key word(s): Personnel Maria Soler Nunez appointed as Head, Group Operations 01.07.2022 / 08:00   Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her tenure with Lonza Group on 1 August 2022, s...
Lonza Group AG
About the publication
01 July 2022 08:00AM
Maria Soler Nunez appointed as Head, Group Operations
CH0013841017
Lonza Group AG / Key word(s): Personnel Maria Soler Nunez appointed as Head, Group Operations 01.07.2022 / 08:00   Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her tenure with Lonza Group on 1 August 2022, s...
Lonza Group AG
About the publication
More Lonza Group AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN